Eurofins Pharma Discovery Services has supported Drug Discovery research for >40 years. We are recognized as the industry leader for providing drug discovery researchers the largest and most diverse p...
Eurofins Pharma Discovery Services has supported Drug Discovery research for >40 years. We are recognized as the industry leader for providing drug discovery researchers the largest and most diverse portfolio of standard and custom in vitro safety & pharmacology assays and panels for drug screening and profiling. In addition to our strengths with in vitro safety pharmacology, we also offer a broad portfolio of over 3500 drug discovery services and 1800 products, including; in vitro assays, cell-based phenotypic assays, safety pharmacology & efficacy, ADME Tox, chemistry and custom proteins and assay development capabilities for a variety of drug discovery targets such as GPCRs, Kinases, Ion Channels, Nuclear Hormone Receptors and other proteins & enzymes. The Eurofins Pharma Discovery Services team was built by bringing together the market leading drug discovery expertise of Panlabs (acquired in 2012), Cerep (acquired in 2013), EMD Millipore's Discovery & Development Solutions business (acquired in 2014), and Villapharma Research (acquired in 2017). With over 400 people in five sites worldwide: St. Charles, MO (USA), Dundee, Scotland (UK), Celle Lévescault (France), Taipei (Taiwan), and Murcia (Spain) our global team offers the high quality, reliable solutions, and support our clients depend on to advance their drug discovery programs. Our broad global service capabilities, and decades of experience in providing drug discovery services, result in the delivery of high quality, reproducible study performance with few repeats and high client satisfaction. The Eurofins Pharma Discovery Services capabilities, expertise, knowledge and skill sets enable us to provide our clients the additional benefit of being able to work with a single outsourcing provider (CRO) for their drug discovery programs.
See more